Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: Group of systemic vasculitis with a strong association with ANCA. The disorders are characterized by necrotizing inflammation of small and medium size vessels, with little or no immune-complex deposits in vessel walls.Vasculitis: Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.Antibodies, Antineutrophil Cytoplasmic: Autoantibodies directed against cytoplasmic constituents of POLYMORPHONUCLEAR LEUKOCYTES and/or MONOCYTES. They are used as specific markers for GRANULOMATOSIS WITH POLYANGIITIS and other diseases, though their pathophysiological role is not clear. ANCA are routinely detected by indirect immunofluorescence with three different patterns: c-ANCA (cytoplasmic), p-ANCA (perinuclear), and atypical ANCA.Microscopic Polyangiitis: A primary systemic vasculitis of small- and some medium-sized vessels. It is characterized by a tropism for kidneys and lungs, positive association with anti-neutrophil cytoplasmic antibodies (ANCA), and a paucity of immunoglobulin deposits in vessel walls.Wegener Granulomatosis: A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and kidneys. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against neutrophil proteinase-3 (WEGENER AUTOANTIGEN).Antibodies, Monoclonal, Murine-Derived: Antibodies obtained from a single clone of cells grown in mice or rats.Remission Induction: Therapeutic act or process that initiates a response to a complete or partial remission level.Peroxidase: A hemeprotein from leukocytes. Deficiency of this enzyme leads to a hereditary disorder coupled with disseminated moniliasis. It catalyzes the conversion of a donor and peroxide to an oxidized donor and water. EC 1.11.1.7.Churg-Strauss Syndrome: Widespread necrotizing angiitis with granulomas. Pulmonary involvement is frequent. Asthma or other respiratory infection may precede evidence of vasculitis. Eosinophilia and lung involvement differentiate this disease from POLYARTERITIS NODOSA.Immunosuppressive Agents: Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.Recurrence: The return of a sign, symptom, or disease after a remission.Glomerulonephritis: Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.Myeloblastin: A polymorphonuclear leukocyte-derived serine protease that degrades proteins such as ELASTIN; FIBRONECTIN; LAMININ; VITRONECTIN; and COLLAGEN. It is named for its ability to control myeloid cell growth and differentiation.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.

*  Antineutrophil cytoplasmic antibody-associated renal vasculitis treated with autologous mesenchymal stromal cells: evaluation...

... associated vasculitis treated with autologous mesenchymal stromal cells (MSCs). A 73-year-old man was admitted to the hospital ... We report the first case of renal antineutrophil cytoplasmic antibody (ANCA)- ... Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / surgery*. Humans. Male. Mesenchymal Stem Cell Transplantation / ... Antineutrophil cytoplasmic antibody-associated renal vasculitis treated with autologous mesenchymal stromal cells: evaluation ...

*  Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis | Otolaryngology | JAMA | The JAMA Network

... associated vasculitis have greatly advanced patient survival but have turned A ... Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies. Curr Opin Rheumatol. 2005;17 ... Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies. Curr Opin Rheumatol. 2005;17 ... Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous ...

*  Learn details of the H1 anti-neutrophil cytoplasmic antibody-associated vasculitis (anca vasculitis) market - WhaTech

ANCA Vasculitis) Global Clinical Trials Review Report provides top level data related to the clinical trials by Region, Country ... Learn details of the H1 anti-neutrophil cytoplasmic antibody-associated vasculitis (anca vasculitis) market Details WhaTech ... Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) market report also provides prominent drugs for in ... Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) market report offers coverage of disease clinical ...

*  ANCA-associated Vasculitis - MPA - ONA

Anti-Neutrophils Cytoplasmic Antibodies (ANCA) Associated Vasculitis. *Wegener's granulomatosis (anti-neutrophil cytoplasmic ... plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil antibody associated vasculitis: an international ... "Antineutrophil cytoplasmic antibodies". Arthritis Rheum. vol. 41. 1998. pp. 1521-1537. (A review of antineutrophil cytoplasmic ... Anti-neutrophil cytoplasmic antibody (ANCA). These should be ordered in patients suspected to have MPA on clinical grounds ( ...

*  Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis - Full Text...

... anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody ... Vasculitis. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Vascular Diseases. Cardiovascular Diseases. Systemic ... Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. The ... The investigators have found that patients with PR3-ANCA-associated vasculitis who remain cytoplasmic anti-neutrophil ...

*  CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis - pdf...

CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis. . ... CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis. ... CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis - ... The appearance of circulating antibodies to neutrophil cytoplasmic antigens ANCA is strongly associated with the development of ...

*  One-Time DNA Study for Vasculitis - Full Text View - ClinicalTrials.gov

Vasculitis. Systemic Vasculitis. Vasculitis, Central Nervous System. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ... Antineutrophil cytoplasmic antibody (ANCA) positive by enzyme immunoassay for either PR3- or MPO-ANCA ... Each type of vasculitis is a rare ('orphan') disease. However, taken together, vasculitis affects tens of thousands of ... The Vasculitis Clinical Research Consortium (VCRC) currently focuses on 6 specific types of vasculitis that were selected to ...

*  CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors - Full Text View -...

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Autoimmune Diseases. Immune System Diseases. Arteritis. Skin ... Systemic Vasculitis. Microscopic Polyangiitis. Polyarteritis Nodosa. Vasculitis. Vascular Diseases. Cardiovascular Diseases. ... Samson M, Puéchal X, Devilliers H, Ribi C, Cohen P, Bienvenu B, Terrier B, Pagnoux C, Mouthon L, Guillevin L; French Vasculitis ... Genetic and Rare Diseases Information Center resources: Microscopic Polyangiitis Polyarteritis Nodosa ANCA-associated ...

*  RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides - Full Text View - ClinicalTrials.gov

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Autoimmune Diseases. Immune System Diseases. Cerebral Small Vessel ... a 2 immunosuppressant regimen for the treatment of relapsing or refractory necrotizing antineutrophil cytoplasmic antibody ( ... Vasculitis. Systemic Vasculitis. Granulomatosis with Polyangiitis. Microscopic Polyangiitis. Churg-Strauss Syndrome. Vascular ... Systemic ANCA positive (+) vasculitides. *Relapsing or refractory vasculitides, resistant to corticosteroids and reference ...

*  A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener&apos...

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Autoimmune Diseases. Immune System Diseases. Cerebral Small Vessel ... anti-CD4, anti-CD5, anti-CD3, and anti-CD11a) ... anti-CD20, anti-CD22, or anti-B-lymphocyte stimulator [BLys]/B- ... Previous treatment with an anti-alpha 4 integrin antibody or co-stimulation modulator ... Systemic Vasculitis. Granulomatosis with Polyangiitis. Microscopic Polyangiitis. Vasculitis. Vascular Diseases. Cardiovascular ...

*  Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA) - Full Text View -...

Vasculitis. Granulomatosis with Polyangiitis. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Microscopic ... Treatment of ANCA-associated vasculitis consists of two phases: remission induction with highly effective, but also relatively ... Genetic and Rare Diseases Information Center resources: Granulomatosis With Polyangiitis ANCA-associated Vasculitis Microscopic ... for the treatment of relapses of ANCA-associated vasculitis (Wegener's granulomatosis or microscopic polyangiitis). Therefore, ...

*  Belimumab in Remission of VASculitis - Full Text View - ClinicalTrials.gov

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Systemic Vasculitis. Autoimmune Diseases. Immune System Diseases. ... anti-proteinase 3. anti-neutrophil cytoplasmic antibody. anti-myeloperoxidase. Granulomatosis with polyangiitis. Vasculitis. ... Tested positive for anti-proteinase 3 (anti-PR3) or anti-myeloperoxidase (anti-MPO) antibodies at any time prior to enrollment. ... Vasculitis Biological: Placebo Biological: Belimumab 10 mg/kg Drug: Azathioprine Phase 3 ...

*  Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis - Full...

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Autoimmune Diseases. Immune System Diseases. Cerebral Small Vessel ... Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an ... Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS ... Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis (PEXIVAS ...

*  American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for...

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Autoimmune Diseases. Immune System Diseases. Vasculitis, Central ... antineutrophil cytoplasmic antibodies [ANCA]), and are now not consistent with some of the current disease definitions. ... Develop new diagnostic and classification criteria for ANCA associated vasculitis and polyarteritis nodosa [ Time Frame: 3 ... Patients without vasculitis, but presenting with similar features to the 6 different types of vasculitis being studied. 1st ...

*  Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis - Full Text View - ClinicalTrials.gov

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Systemic Vasculitis. Vasculitis. Vascular Diseases. Cardiovascular ... Assessment of anti-neutrophil cytoplasmic antibody (ANCA): Number of ANCA-positive patients was counted. ... 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate ... Genetic and Rare Diseases Information Center resources: Granulomatosis With Polyangiitis ANCA-associated Vasculitis ...

*  Study of One Protein Implicated in Wegener Disease - Full Text View - ClinicalTrials.gov

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Systemic Vasculitis. Vasculitis. Vascular Diseases. Cardiovascular ... Group 3: Necrotizing vasculitis with no granulomatous lesions, ± PAUCI immune glomerulonephritis, ± anti-MPO ANCA ... Genetic and Rare Diseases Information Center resources: Granulomatosis With Polyangiitis ANCA-associated Vasculitis ... Group 1: WG, with granulomatous lesions limited to upper airway or lungs and no evidence of generalized vasculitis ,± biopsy ...

*  Diagnosis and management of ANCA associated vasculitis | The BMJ

Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster ... the involve anti-neutrophil cytoplasmic antibody (ANCA) as a common pathogenesis .They can be detected by indirect ... Re: Diagnosis and management of ANCA associated vasculitis. Among the small vessel vasculitis which affects vessels like ... Anti-B cell therapy ( elimination of B lymphocyte with anti-CD 20 antibody) have shown some benefit. Rituximab has found to ...

*  EFFECTS OF EXCESS SODIUM CHLORIDE ON BLOOD LIPIDS: A POSSIBLE FACTOR IN CORONARY HEART DISEASE*† | Annals of Internal Medicine ...

Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies. ... The association between omega-3 fatty acid biomarkers and inflammatory arthritis in an anti-citrullinated protein antibody ...

*  BRUCELLOSIS AND HEART DISEASE. III. CHRONIC VALVULAR HEART DISEASE FOLLOWING NONFATAL BRUCELLOSIS*† | Annals of Internal...

Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies. ... and by studying patients in whom heart disease and brucellosis have been associated. ...

*  Positive predictive value of anti-neutrophil cytoplasmic antibody (ANCA) testing for ANCA-associated systemic vasculitis (AASV)...

Positive predictive value of anti-neutrophil cytoplasmic antibody (ANCA) testing for ANCA-associated systemic vasculitis (AASV ... Positive predictive value of anti-neutrophil cytoplasmic antibody (ANCA) testing for ANCA-associated systemic vasculitis (AASV ...

*  Saitoh M[Author] - PubMed - NCBI

Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Complicated by Periaortitis and Cranial Hypertrophic Pachymeningitis ...

*  ChemoCentryx Announces Immuno-Oncology Data Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics...

... is in Phase II development for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). CCX168 ... In addition, an analysis of tumor-infiltrating cells revealed that the addition of CCX9588 to the anti-PD-L1 antibody ... From the abstract, CCX9588, when delivered in combination with an anti-PDL1 antibody, resulted in significantly reduced primary ... In triple negative breast cancer model, small molecule inhibitor of chemokine receptor CCR1 potentiates anti-tumor effect in ...

*  Chapter 326. The Vasculitis Syndromes | Harrison's Principles of Internal Medicine, 18e | AccessMedicine | McGraw-Hill Medical

Antineutrophil Cytoplasmic Antibodies (ANCA). ++. ANCA are antibodies directed against certain proteins in the cytoplasmic ... neutrophils and monocytes, where they are apparently inaccessible to serum antibodies. However, when neutrophils or monocytes ... Hoffman GS, Specks U: Antineutrophil cytoplasmic antibodies. Arthritis Rheum 41:1521, 1998. [PubMed: 9751084] ... Jayne D et al: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic ...

*  Cees Gm Kallenberg

Risk factors for relapse in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: tools for treatment decisions?. ... vasculitis*antineutrophil cytoplasmic antibodies*immunosuppressive agents*peroxidase*cyclophosphamide*serine endopeptidases* ... What is new with anti-neutrophil cytoplasmic antibodies: diagnostic, pathogenetic and therapeutic implications. C G Kallenberg ... What is new with anti-neutrophil cytoplasmic antibodies: diagnostic, pathogenetic and therapeutic implications. C G Kallenberg ...

*  Medical Information Search (Inflammation • Definitions)

These cytokines influence B-cell development and antibody production as well as augmenting humoral responses.Anti-Inflammatory ... Its production is induced by gamma-interferon and it is required for neutrophil migration into inflamed tissue.Vasculitis: ... cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level ... Neutrophil Infiltration: The diffusion or accumulation of neutrophils in tissues or cells in response to a wide variety of ...

(1/99) Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts.

 (+info)

(2/99) Chimeric IgG4 PR3-ANCA induces selective inflammatory responses from neutrophils through engagement of Fcgamma receptors.

 (+info)

(3/99) CT60 and +49 polymorphisms of CTLA 4 are associated with ANCA-positive small vessel vasculitis.

 (+info)

(4/99) Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study.

 (+info)

(5/99) Small vessel vasculitis.

 (+info)

(6/99) Spontaneous resolution of delayed onset large subclavian artery pseudoaneurysm.

A 70-year-old woman with a history of end-stage renal disease secondary to anti-neutrophil cytoplasmic autoantibody-associated vasculitis had been receiving hemodialysis for 5 years. The patient underwent attempted right internal jugular vein cannulation for temporary hemodialysis catheter placement. Pulsating mass developed in the neck and angiography revealed a subclavian artery pseudoaneurysm 4 days later. The pseudoaneurysm disappeared spontaneously during the interval between the diagnosis and the planned surgical procedure. Such delayed onset and spontaneous resolution of subclavian artery pseudoaneurysm is uncommon. Close observation may be optimal if delayed onset of pseudoaneurysm occurs after small needle puncture with cessation of antiplatelet/anticoagulant administration.  (+info)

(7/99) Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis.

 (+info)

(8/99) Prediction of ESRD in pauci-immune necrotizing glomerulonephritis: quantitative histomorphometric assessment and serum creatinine.

 (+info)



ANCA

  • We report the first case of renal antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis treated with autologous mesenchymal stromal cells (MSCs). (biomedsearch.com)
  • de Groot K, Jayne D. What is new in the therapy of ANCA-associated vasculitides? (jamanetwork.com)
  • take home messages from the 12th workshop on ANCA and systemic vasculitides. (jamanetwork.com)
  • The current classification criteria (American college of Rheumatology 1990 criteria) were developed 20 years ago, before the availability of some important diagnostic tests (e.g. antineutrophil cytoplasmic antibodies [ANCA]), and are now not consistent with some of the current disease definitions. (clinicaltrials.gov)
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) market report helps in identifying prominent locations for conducting clinical trials which saves time and cost. (whatech.com)
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) market report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. (whatech.com)
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Global Clinical Trials Review, H1, 2017" provides an overview of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) clinical trials scenario. (whatech.com)
  • This report provides top line data relating to the clinical trials on Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis). (whatech.com)
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) market report also provides prominent drugs for in-progress trials (based on number of ongoing trials). (whatech.com)
  • Assessment of anti-neutrophil cytoplasmic antibody (ANCA): Number of ANCA-positive patients was counted. (clinicaltrials.gov)
  • In addition to their diagnostic value, it has been suggested that ANCA may have a predictive value for relapse in patients with systemic vasculitis. (clinicaltrials.gov)
  • Granulomatosis with polyangiitis (Wegener's) (WG) and microscopic polyangiitis (MPA) are syndromes of primary systemic vasculitis associated with anti-neutrophil cytoplasm antibodies (ANCA). (clinicaltrials.gov)
  • Together, these syndromes are grouped as ANCA-associated systemic vasculitis (AAV). (clinicaltrials.gov)
  • More recently the small-vessel vasculitides have been divided into antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) and immune-complex mediated vasculitides. (oncologynurseadvisor.com)
  • Included were patients with active severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, ANCA positivity, and resistance to (or intolerance of) cyclophosphamide. (pubmedcentralcanada.ca)
  • Nevertheless, ANCA-associated vasculitis has a high relapse rate, and some patients do not respond satisfactorily to this treatment. (pubmedcentralcanada.ca)
  • B lymphocytes are also instrumental for the production of autoantibodies including ANCA, which in turn have multiple proinflammatory effects that can contribute to the development of tissue injury and vasculitis ( 12 - 15 ). (pubmedcentralcanada.ca)
  • Cytoplasmic antineutrophil cytoplasmic antibody (c-ANCA), perinuclear antineutrophil cytoplasmic antibody (p-ANCA). (thefreedictionary.com)
  • Antineutrophil cytoplasmic autoantibodies (ANCA) are associated with vasculitis and glomerulonephritis. (thefreedictionary.com)
  • c-ANCA (cytoplasmic) is specific for proteinase 3 in neutrophils and monocytes and is found in the sera of patients with Wegener's granulomatosis (WG). (thefreedictionary.com)
  • p-ANCA (perinuclear) is specific for myeloperoxidase, elastase, and lactoferrin, as well as other enzymes in neutrophils. (thefreedictionary.com)
  • Another theory suggests the immune system may be stimulated by an accumulation of the antigenic targets of ANCA due to ineffective destruction of old neutrophils or ineffective removal of neutrophil cell fragments containing proteinase, myeloperoxidase, elastase, lactoferrin, or other proteins. (thefreedictionary.com)

Microscopic Polyangiitis

  • One of the aims of this project is to develop diagnostic criteria for the primary systemic vasculitides (granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis, Churg Strauss syndrome, polyarteritis nodosa, giant cell arteritis, Takayasu arteritis). (clinicaltrials.gov)
  • Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) are primary systemic small vessel vasculitides with predilection for the respiratory tract and kidneys ( 1 ). (pubmedcentralcanada.ca)

Primary Systemic Vasculitis

  • Wegener's granulomatosis is a primary systemic vasculitis characterized by granulomatous and necrotizing inflammation predominantly affecting the respiratory tract and the kidneys. (clinicaltrials.gov)

Systemic Vasculitis

  • Systemic vasculitis is traditionally divided into large-vessel, medium-vessel, and small-vessel vasculitis. (oncologynurseadvisor.com)
  • The diagnosis of systemic vasculitis can be challenging to make, as the symptoms can be nonspecific, and so a high index of suspicion is required to make the diagnosis. (oncologynurseadvisor.com)
  • DAH in conjunction with other manifestations of systemic vasculitis (see section below on common findings) should trigger a workup to establish a diagnosis. (oncologynurseadvisor.com)
  • DAH is the manifestation common to all types of systemic vasculitis, but it is not always present. (oncologynurseadvisor.com)

ANCAs

  • ANCAs (anti-neutrophil cytoplasmic antibodies) are antibodies that attack the body's immune system. (ehow.com)
  • Most patients who suffer from generalized or severe disease activity have circulating antineutrophil cytoplasmic antibodies (ANCAs) reacting either with neutrophil proteinase-3 (PR3) or myeloperoxidase (MPO). (pubmedcentralcanada.ca)

Wegener Granulomatosis

  • Relapse of Wegener granulomatosis (WG) can be associated with occult inflammation and nasal carriage of Staphylococcus aureus. (grandroundsjournal.com)

autoantibodies

  • A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. (jamanetwork.com)

inflammation

  • Vasculitis is group of diseases where inflammation of blood vessels is the common feature. (clinicaltrials.gov)
  • Consisting of a group of six academic medical centers and under the direction of Boston University, the VCRC is dedicated to continuing research to improve the care of patients with WG and other forms of vasculitis (inflammation of the vessels). (ehow.com)
  • Pulmonary vasculitis is characterized by inflammation and destruction of pulmonary vasculature with subsequent tissue necrosis. (oncologynurseadvisor.com)
  • Wegener's syndrome includes granulomatous inflammation of the upper and lower respiratory tract and vasculitis. (thefreedictionary.com)
  • Systemic necrotizing vasculitis is an inflammation of the blood vessels. (thefreedictionary.com)

Wegener's

  • Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. (jamanetwork.com)

diagnosis of vasculitis

  • There are currently no criteria to help doctors make a diagnosis of vasculitis when a patient presents with these non specific symptoms and they are reliant on previous experience and disease definitions. (clinicaltrials.gov)
  • Classification criteria are used to group patients into different types of vasculitis, once a diagnosis of vasculitis has been made, and are useful for studying patients in clinical trials with similar or identical diseases. (clinicaltrials.gov)
  • The diagnosis of vasculitis is a challenge because of the significant overlap in clinical, radiographic, and laboratory features with multiple disease processes, particularly infection and drug reactions. (oncologynurseadvisor.com)
  • As a result, there is often a delay in establishing the diagnosis of vasculitis. (oncologynurseadvisor.com)
  • Once a diagnosis of vasculitis is established, immunosuppressive therapy is usually required. (oncologynurseadvisor.com)

rituximab

  • Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis? (jamanetwork.com)
  • Rituximab is a chimeric monoclonal antibody directed against CD20, a cell surface antigen expressed almost exclusively on cells of B-lymphocyte lineage ( 16 ). (pubmedcentralcanada.ca)

remission

  • Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. (jamanetwork.com)
  • The primary efficacy outcome measure was remission of vasculitis. (clinicaltrials.gov)
  • Complete remission was defined as a Birmingham vasculitis activity score (BVAS) of 0 sustained for at least 2 months. (clinicaltrials.gov)

inflammatory

  • Assessment of anti-inflammatory activity of gusperimus using surrogate marker: number of hematuria-positive patients. (clinicaltrials.gov)
  • High doses of glucocorticoids early in disease, although reduce disease activity due to their anti-inflammatory and immunosuppressive properties, also increase the risk of infection, particularly in the elderly and in the presence of uremia. (clinicaltrials.gov)

cyclophosphamide

  • The prolonged and repeated use of cyclophosphamide is associated with substantial toxicity, which ultimately limits or prohibits its use in some patients. (pubmedcentralcanada.ca)

manifestation

predominantly

  • Histologically, the pseudotumor exhibited predominantly storiform-patterned fibrosis, dense plasma cell infiltrates, neutrophils, nuclear dust and angiocentric fibrosis (i.e., chronic localized fibrosing vasculitis), which coexisted with granular degeneration and mummification of collagen, stellate necrosis, and rare granulomas: diagnostic histologic features of limited orbital WG. (grandroundsjournal.com)

immune

  • Antineutrophil cytoplasmic antibody-associated renal vasculitis treated with autologous mesenchymal stromal cells: evaluation of the contribution of immune-mediated mechanisms. (biomedsearch.com)
  • The immune complex mediated vasculitides are Henoch-Schönlein purpura, IgA nephropathy, Behçet's disease, and essential cryoglobulinemia. (oncologynurseadvisor.com)
  • B lymphocytes are critical for the regulation of immune responses and production of antibodies. (pubmedcentralcanada.ca)

findings

classification

  • Therefore to progress future research in vasculitis, it is important that the classification criteria are updated. (clinicaltrials.gov)

clinical

  • 4. Their disease had to be active, as measured with BVAS in which clinical manifestations caused by active vasculitis are scored on a list of predefined organ-specific items. (clinicaltrials.gov)
  • The National Institutes of Health provided a grant to establish the Vasculitis Clinical Research Consortium (VCRC). (ehow.com)

Treatment

  • End-stage liver disease occurs when the complications associated with liver disease can no longer be controlled through medical treatment. (ehow.com)

types

  • We will recruit 260 patients with each of the 6 types of vasculitis and compare them with 1300 controls (patients with the 5 other types of vasculitis), in order to determine the optimal combination of symptoms, signs and investigations that classify each person into the appropriate group. (clinicaltrials.gov)
  • There are two types of cytoplasmic neutrophil antibodies, identified by their cellular staining characteristics. (thefreedictionary.com)

blood

  • No sinusitis, other localized infection, or systemic disease was identified by physical examination, imaging, or laboratory studies (negative blood cultures and antineutrophil cytoplasmic antibodies). (grandroundsjournal.com)

patients

  • We, the investigators, will do this by studying a large group of patients with vasculitis and comparing them to a large group of patients that present in a similar way, but do not have vasculitis. (clinicaltrials.gov)

common

  • These symptoms are very common among many different diseases, not just vasculitis. (clinicaltrials.gov)
  • Systemic lupus erythematosus, mixed connective tissue disease, and antiphospholipid syndrome are the common connective tissue diseases associated with pulmonary vasculitis. (oncologynurseadvisor.com)

patient